Evidence map›Paper›PMID 35429403›Full record

ArticleThe Journal of infectious diseases2022

Recurrent Respiratory Syncytial Virus Infection in a CD14-Deficient Patient.

Sjanna B Besteman, Emily Phung, Henriette H M Raeven, Gimano D Amatngalim, Matevž Rumpret, Juliet Crabtree, Rutger M Schepp, Lisa W Rodenburg, Susanna G Siemonsma, Nile Verleur and 16 more

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 9 institutions in 2 countries.

Sjanna B BestemanCenter for Translational Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands.
Emily PhungVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Henriette H M RaevenDepartment of Pediatric Pulmonology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Gimano D AmatngalimDepartment of Pediatric Pulmonology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Matevž RumpretCenter for Translational Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands.
Juliet CrabtreeDepartment of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Rutger M ScheppNational Institute of Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Lisa W RodenburgDepartment of Pediatric Pulmonology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Susanna G SiemonsmaCenter for Translational Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands.
Nile VerleurDepartment of Pediatrics, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, the Netherlands.
Rianne van SlootenCenter for Translational Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands.
Karen DuranDepartment of Genetics, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.
Gijs W van HaaftenDepartment of Genetics, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.
Jeffrey M BeekmanDepartment of Pediatric Pulmonology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Lauren A ChangVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Linde MeyaardCenter for Translational Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands.
Tjomme van der BruggenDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands.
Guy A M BerbersNational Institute of Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Nicole DerksenRSV Patient Network, ReSVinet, Zeist, the Netherlands.
Stefan NierkensCenter for Translational Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands.
Kaitlyn M MorabitoVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Tracy J RuckwardtVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Evelyn A Kurt-JonesDepartment of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Douglas GolenbockDepartment of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Barney S GrahamVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Louis J BontCenter for Translational Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands.
University Medical Center Utrecht · NLNational Institutes of Health · USUniversity of Massachusetts Chan Medical School · USNational Institute for Public Health and the Environment · NLNational Institute of Allergy and Infectious Diseases · USOncode Institute · NLWilhelmina Children's Hospital · NLPension Fund for Care and Well-Being · NLUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecurrent respiratory syncytial virus (RSV) infection requiring hospitalization is rare and the underlying mechanism is unknown. We aimed to determine the role of CD14-mediated immunity in the pathogenesis of recurrent RSV infection.

methodsWe performed genotyping and longitudinal immunophenotyping of the first patient with a genetic CD14 deficiency who developed recurrent RSV infection. We analyzed gene expression profiles and interleukin (IL)-6 production by patient peripheral blood mononuclear cells in response to RSV pre- and post-fusion (F) protein. We generated CD14-deficient human nasal epithelial cells cultured at air-liquid interface (HNEC-ALI) of patient-derived cells and after CRISPR-based gene editing of control cells. We analyzed viral replication upon RSV infection.

resultsSanger sequencing revealed a homozygous single-nucleotide deletion in CD14, resulting in absence of the CD14 protein in the index patient. In vitro, viral replication was similar in wild-type and CD14-/- HNEC-ALI. Loss of immune cell CD14 led to impaired cytokine and chemokine responses to RSV pre- and post-F protein, characterized by absence of IL-6 production.

conclusionsWe report an association of recurrent RSV bronchiolitis with a loss of CD14 function in immune cells. Lack of CD14 function led to defective immune responses to RSV pre- and post-F protein without a change in viral replication.

Indexed as

Respiratory Syncytial Virus InfectionsCytokinesHumansLeukocytes, MononuclearLipopolysaccharide ReceptorsRespiratory Syncytial Virus, HumanCytokinesLipopolysaccharide ReceptorsCD14epitheliummonocyterespiratory syncytial virusToll-like receptor

Identifiers

PMID35429403
PMCPMC9400420
OpenAlexW4224124219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.